Everything you need to know about hybrid/decentralized trials

Register free: https://www.pharmtech.com/pt/know

Event Overview:
With more than 50% of trials expected to be decentralized by 2024, many sponsors and CROs are learning that decentralizing clinical trials is not just for a pandemic. But despite adoption, there are still questions, myths, and rumors about what it means to “decentralize a trial”.
Listen in as experts from Medable and Incyte compare traditional trials (design first, patient second) with patient-centered trials (patient first, design second) and discuss how adopting a decentralized approach can help any organization, regardless of size or therapeutic areas focus, reimagine their existing approach to choreograph a masterfully designed patient-centered trial.

Key Learning Objectives:
In this on-demand webinar, you will learn:

• The fundamentals of decentralized clinical trials
• Use cases for hybrid and fully decentralized approaches
• Benefits of designing patient-centered clinical trials

Who Should Attend:

• Pharma Sponsors, Biotechs companies, CROs, University Research heads
  • Clinical operations / development professionals
  • TA lead professionals
  • R&D IT / technology professionals
  • Founder/ President/ CEO/ Executive Directors
  • Chief Medical Officers / Chief Scientific Officers/ Chief Innovation Officers
  • Clinical trial strategy team professionals
  • Heads of data sciences & innovation
  • Digital health professionals

Claire Marsden
VP, DCT Solutions
Medable

Worked in the industry for over 25 years across all phases of clinical development in multiple sectors including Big Pharma (GSK, Pfizer, Novartis, Bayer), Biotech (Alnylam, Lexicon) and within the CRO space (Quintiles/IQVIA, Covance/LabCorp). Over the past 15 years have led Global teams in Project Management (Cardiovascular/Metabolic), Project Costing and Operational Strategy & Design and been instrumental in seeking, designing, and executing innovative solutions for client portfolios to meet the evolving and future needs of drug development. In her role within Medable, Claire will be collaborating with our clients and internal teams to shape DCT solutions that are designed around the patient to optimise inclusivity and operational efficiency to transform drug development and registration.

John Galvin
Senior Medical Director, US Medical Affairs
Incyte

Dr. John Galvin MD, MS, MPH is a hematologist in Chicago, IL and is Senior Medical Director, US Medical Affairs for Incyte Pharmaceuticals. Dr. Galvin is also affiliated with the University of Illinois Cancer Center. He has been in practice 11 years. He also has an affiliation with Northwestern University’s department of Immunology & Microbiology. He specializes in hematologic oncology with a focus on stem cell transplantation and graft versus host disease.

Register free: https://www.pharmtech.com/pt/know